ACIP votes to expand recommendation for Pfizer’s RSV vaccine ABRYSVO to include adults aged 50 – 59 at increased risk of disease
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Subscribe To Our Newsletter & Stay Updated